(NHI) National Health Investors - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US63633D1046

NHI: Sale-Leasebacks, Joint Ventures, Financing

National Health Investors, Inc. (NYSE: NHI), incorporated in 1991, operates as a real estate investment trust (REIT) focused on healthcare and senior housing properties. The company specializes in structuring investments through sale-leaseback transactions, joint ventures, and mortgage and mezzanine financing. Its portfolio includes independent living communities, assisted living and memory care facilities, skilled nursing centers, and specialty hospitals, primarily catering to the growing demand for age-related healthcare services. NHIs investments are diversified across need-driven and discretionary senior housing, ensuring a balanced exposure to both essential and elective care segments. The company has established a strong presence in over 20 states, with a portfolio exceeding 240 properties, generating consistent cash flows through long-term leases with healthcare operators. Web URL: https://www.nhireit.com

Ticker Symbol: NHI
Exchange: NYSE
Type: common stock
Country Origin: United States
GICS Sub Industry: Health Care REITs

3 Month Forecast:
Based on current price action and technical indicators, NHIs stock is expected to trade within a range of $72 to $78 over the next three months. The SMA 20 ($73.59) and SMA 50 ($72.38) indicate a bullish crossover, suggesting potential upside. However, the SMA 200 ($73.08) may act as a resistance level. Average trading volume (20d: 237,807 shares) and ATR (2.09) suggest moderate volatility.
With a market cap of $3.54B and forward P/E of 12.84, NHI is positioned for stable growth. The P/B ratio (2.59) reflects strong asset valuation, while the P/S ratio (10.54) indicates premium pricing. A return on equity (RoE) of 10.10% aligns with industry averages, supporting dividend sustainability. Expect NHI to maintain its dividend yield and potentially expand its portfolio through strategic acquisitions.

Additional Sources for NHI Stock

NHI Stock Overview

Market Cap in USD 3,538m
Sector Real Estate
Industry REIT - Healthcare Facilities
GiC Sub-Industry Health Care REITs
IPO / Inception 1991-10-09

NHI Stock Ratings

Growth Rating 50.9
Fundamental 44.7
Dividend Rating 38.8
Rel. Strength 5.53
Analysts 3.88/5
Fair Price Momentum 78.18 USD
Fair Price DCF 92.16 USD

NHI Dividends

Dividend Yield 12m 4.89%
Yield on Cost 5y 9.41%
Annual Growth 5y -3.99%
Payout Consistency 93.8%

NHI Growth Ratios

Growth Correlation 3m 84%
Growth Correlation 12m 32.4%
Growth Correlation 5y 55%
CAGR 5y 14.52%
CAGR/Max DD 5y 0.46
Sharpe Ratio 12m 1.36
Alpha 17.44
Beta 0.370
Volatility 21.78%
Current Volume 166.2k
Average Volume 20d 230.4k
What is the price of NHI stocks?
As of May 02, 2025, the stock is trading at USD 75.37 with a total of 166,178 shares traded.
Over the past week, the price has changed by +0.07%, over one month by +1.48%, over three months by +11.06% and over the past year by +24.91%.
Is National Health Investors a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, National Health Investors (NYSE:NHI) is currently (May 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 44.70 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NHI as of May 2025 is 78.18. This means that NHI is currently overvalued and has a potential downside of 3.73%.
Is NHI a buy, sell or hold?
National Health Investors has received a consensus analysts rating of 3.88. Therefor, it is recommend to buy NHI.
  • Strong Buy: 3
  • Buy: 1
  • Hold: 4
  • Sell: 0
  • Strong Sell: 0
What are the forecast for NHI stock price target?
According to ValueRays Forecast Model, NHI National Health Investors will be worth about 84.8 in May 2026. The stock is currently trading at 75.37. This means that the stock has a potential upside of +12.56%.
Issuer Forecast Upside
Wallstreet Target Price 80.9 7.3%
Analysts Target Price 79.6 5.6%
ValueRay Target Price 84.8 12.6%